FDA Issues Draft Guidance on Three-Year Clinical Investigation Exclusivity for NDAs and Supplements

Details of the Update

The draft guidance outlines documentation standards that applicants should follow when requesting three-year clinical investigation of exclusivity. It provides detailed recommendations on how to present the information required to support an exclusivity request as part of an NDA or NDA supplement submission. 

The guidance applies to both original NDAs and NDA supplements that rely on new clinical studies. By clarifying expectations around the format and supporting information required, the FDA aims to improve consistency in how applicants submit exclusivity requests. 

In addition, the agency notes that the guidance will continue to evolve. Future updates may include additional questions and answers as new regulatory scenarios arise, and as feedback from stakeholders is incorporated. 

Feedback Deadline

Stakeholders may submit comments on the FDA draft guidance regarding three-year clinical investigation exclusivity until May 4, 2026. Comments can be submitted through the FDA’s online or written submission channels. 

Why It Matters

The draft guidance provides greater regulatory clarity around eligibility and documentation requirements for three-year data exclusivity associated with drug approvals in the United States. Clearer expectations can help streamline submission preparation, support regulatory consistency, and reduce uncertainty for sponsors preparing NDAs or supplements supported by new clinical investigations. 

Who This Is Relevant For

This update is particularly relevant for pharmaceutical manufacturers, clinical sponsors, regulatory affairs teams, and compliance professionals responsible for preparing NDA submissions or supplements supported by clinical studies. Organizations involved in drug development and market authorization processes in the U.S. should review the draft guidance to understand its implications for exclusivity requests. 

Next Steps

Regulatory teams should review the draft FDA guidance on three-year clinical investigation exclusivity and assess how it may affect current or planned NDA and NDA supplement submissions. Stakeholders may also consider preparing comments, feedback, or clarification questions for submission before the May 4, 2026 comment deadline. 

Organizations managing multiple regulatory submissions across markets may also benefit from centralized regulatory intelligence tools that help track evolving guidance and submission expectations. 

RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now. 

Next Steps

Stakeholders should review the updated FDA infant formula web resources and the newly published market list to ensure that internal records and public-facing product information are aligned.

Regulatory, quality, and commercial teams should verify that product listings and company information are accurately reflected in the public database. Organizations may also consider monitoring future transparency initiatives under Operation Stork Speed to remain informed about potential policy developments or regulatory actions.

As regulatory transparency initiatives continue to evolve, maintaining visibility into global regulatory updates becomes increasingly important. RegASK helps organizations monitor regulatory developments and manage compliance with workflows across multiple jurisdictions.

RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now. 

FAQs

What is the FDA’s draft guidance on three-year clinical investigation exclusivity? 

The FDA draft guidance issued on March 4, 2026 provides recommendations for applicants seeking three-year clinical investigation exclusivity for new drug applications (NDAs)orNDA supplements. It explains the eligibility criteria and outlines the content and format expected for exclusivity requests. 

Who can apply for three-year clinical investigation exclusivity? 

Applicants submitting original NDAs or NDA supplements supported by new clinical investigations may request three-year exclusivity, provided they meet the statutory and regulatory eligibility requirements outlined by the FDA. 

When is the deadline to submit comments on the FDA draft guidance? 

Stakeholders may submit feedback on the draft guidanceuntilMay 4, 2026, using the FDA’s online or written submission channels. 

How can RegASK support companies managing GMO labeling requirements?

RegASK provides AI-powered regulatory intelligence and workflow automation that enables organizations to monitor FDA guidance updates, regulatory changes, and submission requirements across global markets. This helps regulatory and compliance teams stay informed, assess regulatory impact, and streamline submission preparation.